Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of LY900014 to Insulin Lispro in Adults With Type 2 Diabetes
NCT03952143Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2019
- Primary completion
- Jan 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of insulin lispro in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change From Baseline in Hemoglobin A1c at 26 weeks. Started May 2019; status: completed.
02
Drugs
insulin lispro
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03952143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03952143.